Table 1. Baseline demographics in EGFR positive and negative lung adenocarcinoma subjects.
| EGFR positive | EGFR negative | Total | p-value | |
|---|---|---|---|---|
| Number(n) (%) | 388 (38.0)1 | 632 (62.0) | 1,020 | |
| Age | 66.2 ± 11.5 | 67.2 ± 11.4 | 66.8 ± 11.42 | 0.190 |
| Sex | <0.001 | |||
| Male | 154 (39.7) | 441 (69.8) | 595 (58.3) | |
| Female | 234 (60.3) | 191 (30.2) | 425 (41.7) | |
| Low BMI (<18.5 kg/m2) | 28 (7.2) | 63 (10.0) | 91 (8.9) | 0.134 |
| Smoking status (n = 1,017)3 | <0.001 | |||
| Ever smoker | 97/387 (25.1) | 323/630 (51.3) | 420/1017 (41.3) | |
| Never smoker | 290/387 (74.9) | 307/630 (48.7) | 597/1017 (58.7) | |
| Smoking amount in smoker, pack-years | 27.9 ± 18.2 | 37.1 ± 20.5 | 35.0 ± 20.3 | <0.001 |
| Stage (n = 1012)3 | 0.001 | |||
| III | 43/386 (11.1) | 121/626 (19.3) | 164/1012 (16.2) | |
| IV | 343/386 (88.9) | 505/626 (80.7) | 848/1012 (83.8) | |
| Treatment | ||||
| Chemotherapy | 321 (82.7) | 442 (69.9) | 763 (74.8) | <0.001 |
| TKI | 284 (73.2) | 131 (20.7) | 415 (40.7) | <0.001 |
| Radiation therapy | 106 (27.3) | 166 (26.3) | 272 (26.7) | 0.712 |
| FEV1 (n = 706)3 | 79.2 ± 19.3 | 76.0 ± 20.3 | 77.2 ± 20.0 | 0.041 |
| FVC (n = 706)3 | 77.6 ± 17.7 | 78.0 ± 17.3 | 77.9 ± 17.4 | 0.745 |
| CCI | 5.6 ± 2.2 | 5.9 ± 2.2 | 5.8 ± 2.2 | 0.044 |
| Median overall survival, month (95% CI) | 22.8 (20.5–25.0) | 10.0 (8.9–11.1) | 13.8 (12.2–15.5) | <0.001 |
1Number (%);
2Mean+/- SD; BMI, body mass index;
3Differences in total number are due to missing values. TKI, tyrosine kinase inhibitor; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; CCI, Charlson comorbidity index; CI, confidence interval.